Commit and Ph body fluid - a phase IV clinical study of FDA data
Summary:
We study 4,902 people who take Commit (nicotine polacrilex) or have Ph body fluid. No report of Ph body fluid is found in people who take Commit.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Commit?
Commit has active ingredients of nicotine polacrilex. eHealthMe is studying from 4,842 Commit users. Check the latest studies of Commit.
What is Ph Body Fluid?
Ph body fluid is found to be associated with 44 drugs and 63 conditions by eHealthMe. Check the latest studies of Ph body fluid.
No report is found.
Do you take Commit and have Ph body fluid?
- Check whether Ph body fluid is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Commit:
- Commit (4,842 reports)
Ph body fluid treatments and more:
- Ph body fluid (60 reports)
How severe was Ph body fluid and when was it recovered:
Expand to all the drugs that have ingredients of nicotine polacrilex:
Browse all side effects of Commit:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Ph body fluid:
Browse all the conditions that are associated with Ph body fluid:
How the study uses the data?
The study uses data from the FDA. It is based on nicotine polacrilex (the active ingredients of Commit) and Commit (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Doxazosin Mesylate and Nifedipine drug interactions for men aged 40-49 - now
- Fentanyl and Psoriasis for Women aged 60+ - now
- Fentanyl and Plaque Psoriasis for Women aged 60+ - a second ago
- Diphenhydramine Hydrochloride and Meclizine drug interactions for men aged 50-59 - 3 seconds ago
- Aleve and Chronic Obstructive Pulmonary Disease for Women aged 60+ - 4 seconds ago
- Flomax and Fosamax drug interactions for women aged 60+ - 4 seconds ago
- Aleve and Chronic Obstructive Lung Disease for Women aged 60+ - 4 seconds ago
- Aleve and Chronic Obstructive Airway Disease for Women aged 60+ - 4 seconds ago
- Aleve and Copd for Women aged 60+ - 5 seconds ago
- Naproxen and Nasal Decongestion Therapy for Men aged 60+ - 6 seconds ago